Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus

BACKGROUND: Absorption of current rapid-acting insulins is too slow for patients with diabetes mellitus to achieve optimal postprandial glucose control. Faster-acting insulin aspart (faster aspart) is insulin aspart in a new formulation with faster early absorption. We compared the pharmacokinetic/p...

Descripción completa

Detalles Bibliográficos
Autores principales: Heise, Tim, Stender-Petersen, Kirstine, Hövelmann, Ulrike, Jacobsen, Jacob Bonde, Nosek, Leszek, Zijlstra, Eric, Haahr, Hanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5425492/
https://www.ncbi.nlm.nih.gov/pubmed/27878566
http://dx.doi.org/10.1007/s40262-016-0473-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5425492/
https://www.ncbi.nlm.nih.gov/pubmed/27878566
http://dx.doi.org/10.1007/s40262-016-0473-5

Ejemplares similares